BioMarin Pharmaceutical Inc. (BMRN) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
BioMarin Pharmaceutical Inc. (BMRN) surged +2.66% to $57.49 as options desks priced 60% call premium vs. 40% put protection around the $56 max-pain magnet. Solid 78% profit margin (6% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of Oc
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential to be the first
For questions about this article or underlying research, email help@trefis.com.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to
For questions about this article or underlying research, email help@trefis.com.
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMRN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMRN. Explore sector supply chains on /butterfly.
Why BMRN Stock surged +2.66% Today — RQD Quant Desk Flash. Solid 78% profit margin (6% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.